Hippocampal Atrophy: Another Common Pathogenic Mechanism of Depressive Disorders and Epilepsy?

A. Kanner

DOI: https://doi.org/10.5698/1535-7511-11.5.149

2011-09-01

Epilepsy Currents

Abstract:Commentary Since the arrival of MRI of the brain, hippocampal atrophy (HA) has been recognized as the most frequent neuroradiologic abnormality in temporal lobe epilepsy (TLE). The use of volumetric measurements of temporal lobe structures on MRI facilitated the recognition of subtle HA, not identified by visual exam, including HA contralateral to the seizure focus in patients with unilateral TLE. In psychiatry, the use of volumetric measurements has revolutionized our understanding of the pathogenic role played by temporal and frontal lobes in mood disorders. In fact, bilateral HA has become one the most frequent neuroradiologic findings in major depressive disorders (MDD), but volumetric measurements are necessary to detect the 10 to 20 percent volume loss in this condition (1). Sheline et al. were the first to report bilateral HA in a group of women with recurrent MDD (1). The magnitude of the decrease in hippocampal volumes was correlated with the duration of the depressive episode, and in particular with the duration of “untreated” depression (2). Hippocampal atrophy in MDD can be detected after recurrent MDDs (1, 3); it is a trait of this disease, as patients with a remitted depressive episode, off antidepressant medication, continue to have smaller posterior hippocampal volumes (3). In addition to measuring the volume of mesial temporal structures, investigators have examined changes in the shape of the hippocampal formation with high–dimension brain mapping. This method revealed surface deformations at the level of the subiculum (4) and in CA1-CA3 cell fields (5). As in the case of mesial temporal sclerosis in TLE, the presence of HA in MDD has been associated with memory deficits (6). Thus, it is not surprising that in the study selected for this commentary, Finegersh et al. found that depressive symptomatology was associated with bilateral HA in patients with unilateral TLE. Is it possible that the presence of bilateral HA in depressed patients with epilepsy may account for the worse response of the seizure disorder to pharmacologic, surgical therapy, or both reported in recent years (7, 8)? In one study of 780 patients with new-onset epilepsy, a history of depression preceding the onset of the seizure disorder was associated with a two-fold higher risk to develop treatment-resistant epilepsy (7). Likewise, in a study of 138 patients with new-onset epilepsy, the identification of symptoms of depression, anxiety, or both at the time of diagnosis of epilepsy was associated with a significantly lower probability of seizure-freedom at 12-month follow-up (8). In MDD, HA is also associated with a worse prognosis, as evidenced by the higher risk of recurrence of MDD in these patients (9). The HA in MDD has been attributed to high cortisol serum concentrations associated with a hyperactive hypothalamicpituitary-adrenal axis, which has been demonstrated in up to 50% of patients with the dexamethasone suppression test (DST). These high cortisol levels are a trait, as nonsuppression in the DST has been found in patients who have remitted from an MDD. In experimental studies with rats and monkeys, high concentrations of cortisol were found to be neurotoxic as they were associated with 1) damage of hippocampal neurons, particularly CA3 pyramidal neurons mediated by reduction Bilateral Hippocampal Atrophy in Temporal Lobe Epilepsy: Effect of Depressive Symptoms and Febrile Seizures.